Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database
Abstract This study aims to monitor and identify adverse events (AEs) associated with cetuximab, a drug used to treat various late-stage (metastatic) tumors, to improve patient safety and guide drug use. This study retrospectively analyzed the cases reported in the FDA adverse event reporting system...
Saved in:
Main Authors: | Shuai Zhao, Yan Wang, Xiaoli Deng, Xi Chen, Zhaoyi Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-88838-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01) -
Challenges in setting up the antiretroviral paediatric registry in South Africa: Lessons learned from Free State Province clinics
by: B R Omotoso, et al.
Published: (2024-07-01) -
Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01) -
High risk for life-threatening adverse events of fluoroquinolones in young adults: a large German population-based cohort study
by: Julia Wicherski, et al.
Published: (2025-02-01) -
Characteristics and contributing factors of adverse drug reactions: an analytical study of patients with tuberculosis receiving treatment under the National TB Program of India [version 2; peer review: 1 approved, 2 approved with reservations, 1 not approved]
by: Jay Patel, et al.
Published: (2024-07-01)